Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell co-transplantation in haploidentical nonmyeloablative stem cell transplantation for high-risk acute leukemia
ACTRN12608000129381Phase 2Recruiting
- Sponsor
- Huisheng Biopharmaceutical
- Start
- Mar 2008
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mesenchymal stem cells in Acute Leukaemia (2 arms), sponsored by Huisheng Biopharmaceutical. Primary endpoints: Transplant-related mortality, Incidence of graft-versus-host disease and 1 more. Started Mar 2008; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on ACTRN12608000129381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000129381.